| 1 |
Discovery of PIP5Kgamma inhibitor for treatment of Parkinson's disease |
| Small Molecules |
Parkinson's disease |
PIP5Kγ |
Hit |
K.MEDI hub |
RS-2023-00283494 |
|
| 2 |
Development of a novel c.Abl and LRRK2 dual inhibitor for Parkinson’s Disease Treatment |
| Small Molecules |
Parkinson's disease |
c.Abl/LRRK2 |
Phase 1 |
1ST Biotherapeutics Inc. |
RS-2023-00283009 |
|
| 3 |
Non.clinical development of ALS disease treatment using a small molecule compound that inhibits aggregation of SOD1 protein |
| Small Molecules |
Amyotrophic Lateral Sclerosis |
SOD1 |
Preclinical |
PRG S&Tech Inc. |
RS-2023-00258714 |
|
| 4 |
Discovery of Lead Candidates for Parkinson’s disease targeting novel TAS2R GPCR |
| Small Molecules |
Parkinson's disease |
TAS2R |
Lead |
DIGMBIO |
RS-2023-00219269 |
|
| 5 |
Development of therapeutic agent for Parkinson's disease targeting alpha synuclein aggregates using autophagy targeting chimera (AUTOTAC) |
| Small Molecules |
Parkinson's disease |
α-Syn |
Hit |
AUTOTAC Bio Inc. |
RS-2022-00166787 |
|
| 6 |
Development of a lead compound for preventing Parkinson’s disease using small compounds with inhibitory mechanism of initial alpha-synuclein aggregation |
| Small Molecules |
Parkinson's disease |
α-synuclein |
Hit |
Hanyang University |
HN21C1258 |
|
| 7 |
Lead identification of ASK1 inhibitor as a therapeutic agent for Parkinson’s disease |
| Small Molecules |
Parkinson's disease |
ASK1 |
Lead |
Korea Research Institute of Chemical Technology |
HN21C1139 |
|
| 8 |
Discovery of Lead Compounds for the Treatment of Progressive Supranuclear Palsy by Controlling 4R Tauopathy |
| Small Molecules |
Progressive supranuclear palsy, 4R tauopathies |
4R tau oligomer |
Lead |
Korea Institute of Science and Technology |
HN21C0315 |
|
| 9 |
Development of lead compound for treatment of hearing loss caused by cisplatin |
| Small Molecules |
Hearing loss |
DRAK1, ADCK4, CDC42BPA |
Hit |
Kyungpook National University |
HN21C0107 |
|
| 10 |
Development of lead compounds as antidepressant having both α2 adrenergic antagonist and NDRI activities |
| Small Molecules |
Major depressive disorder |
A2 adrenergic, NDRI |
Hit |
Kyung Hee University |
HN21C1076 |
|
| 11 |
Development of KV7.4 specific activator for the treatment of genetic hearing loss(DFNA2) |
| Small Molecules |
Genetic Hearing Loss |
KV7.4 |
Lead |
Yonsei University |
HN21C0163 |
|
